adverse events were neutropenia (≈33%) and infusion-related reactions (≈20%). The study 16 showed that obinutuzumab/chlorambucil induced deeper and longer remissions than rituximab/chlorambucil, and the FDA subsequently approved the combination of
Search Results
New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients
Neel K. Gupta and Charalambos Andreadis
The Top Five in Oncology: Where Do We Go From Here?
Harold J. Burstein
. No white cell–stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication. If the ancient adage, “First, do no harm” is still sacred, then the next line would be “Second, do no
NCCN Guidelines® Updates
cytopenia(s),” “or increased marrow blasts” was added. Following “Clinically relevant thrombocytopenia or neutropenia,” “or increased marrow blasts” was added. “No response” was changed to “Disease progression/no response.” Footnote “bb” was added
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar
to toxicity, 6 patients experienced nonhematologic grade 3/4 adverse events (20%), including muscle weakness, sepsis, and pneumonia; neutropenia and thrombocytopenia were seen in 2 patients (10%). 14 Based on data from the 3 phase II studies, 8 , 10
Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack
Jason D. Goldman, Amelia Gallaher, Rupali Jain, Zach Stednick, Manoj Menon, Michael J. Boeckh, Paul S. Pottinger, Stephen M. Schwartz, and Corey Casper
cell transplantation (HSCT). These ambulatory patients are highly immunosuppressed, including deep and prolonged neutropenia, and often require intensive therapies, such as daily infusions or transfusion support. 11 Adults requiring hospitalization are
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Sven De Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Francisco Hernandez-Ilizaliturri, Eric Hsi, Boyu Hu, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar
was also associated with a lower incidence of treatment discontinuations related to TEAEs. Grade ≥3 TEAEs, including neutropenia, diarrhea, and increased levels of alanine transaminase and aspartate aminotransferase, were reported in 12%, 10%, 6
AIDS-Related Kaposi Sarcoma, Version 2.2019
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC, and Deborah A. Freedman-Cass
malignancies). 39 – 43 In particular, chemotherapy can cause neutropenia, which is a major risk factor for the development of infections. 44 Newer targeted agents are also associated with immunosuppression and increased infection risk. 45 The frequency and
Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer
Ryan D. Gentzler and Jyoti D. Patel
significant differences in survival were seen among the 4 regimens. Patients receiving carboplatin and paclitaxel had a lower incidence of grade 3 and 4 nausea, vomiting, and febrile neutropenia. From this point on, carboplatin and paclitaxel became the most
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Featured Updates to the NCCN Guidelines
Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan Madanat, Lori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, and Cindy Hochstetler
discussed the addition of eltrombopag to immunosuppressive therapy (IST) for patients with lower-risk MDS, and voted to modify a footnote (see MDS-3 , page 108). In the setting of clinically relevant thrombocytopenia or neutropenia, IST is recommended as an
New Approaches to Endocrine Therapy for Breast Cancer
William J. Gradishar
monitor WBC counts in patients receiving palbociclib and ribociclib, but those who develop neutropenia “generally don't feel the effects” and febrile neutropenia is uncommon, he indicated. “As we move forward,” he added, clinicians can expect “the coming
